Fundraising FoxVenaxis
Castle Rock, US · Nevada corporation
Find your way into Venaxis
Sign up to see every warm intro you have to Venaxis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Venaxis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
ST
Stephen T. LundyExecutive
JG
Jeffrey G. McGonegalExecutive
Board
DE
David E. WelchBoard director
SA
Stephen A. WilliamsBoard director
GS
Gail S. SchoettlerBoard director
DJ
Daryl J. FaulknerBoard director
SA
Susan A. EvansBoard director
Reported raises · per SEC filings
Form D private placements$53M disclosed across 5 rounds · 2016–2019
▶$7.1MraisedFeb 2019 · 3 investors · Other TechnologyRule 506(b)
▶$7.1MraisedFeb 2019 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Rob ChangExecutive Officer
- Remo ManciniExecutive Officer
- Jeffrey G. McGonegalExecutive Officer
- Benjamin YiExecutive Officer
- Jason LesExecutive Officer
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Jan 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$37MraisedDec 2017 · 32 investors · OtherRule 506(b)
▶$37MraisedDec 2017 · 32 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoDirector
- Jason LesDirector
- Jeffrey G. McGonegalExecutive Officer
- John R. O'RourkeExecutive Officer, Director
- Andrew KaplanDirector
- Offering amount
- $37M
- Amount sold
- $37M
- Finders' fees
- $500K
- First sale
- Dec 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.3MraisedMar 2017 · 6 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2017 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey G. McGonegalExecutive Officer
- John R. O'RourkeDirector
- Mike T. DaiDirector
- Stephen T. LundyExecutive Officer, Director
- Michael M. BeeghleyDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Mar 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$4.8MraisedMar 2017 · 10 investors · BiotechnologyRule 506(b)
▶$4.8MraisedMar 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mike T. DaiDirector
- Jeffrey G. McGonegalExecutive Officer
- Michael M. BeeghleyDirector
- Stephen T. LundyExecutive Officer, Director
- John R. O'RourkeDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- Finders' fees
- $200K
- First sale
- Mar 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1.9MraisedSep 2016 · 17 investors · Other Health CareRule 506(b)
▶$1.9MraisedSep 2016 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David E. WelchDirector
- Stephen A. WilliamsDirector
- Gail S. SchoettlerDirector
- Stephen T. LundyExecutive Officer, Director
- Daryl J. FaulknerDirector
- Susan A. EvansDirector
- Jeffrey G. McGonegalExecutive Officer
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Sep 2016
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Venaxis raised?
- Venaxis has disclosed $53M raised across 5 rounds.
- Where is Venaxis headquartered?
- Venaxis is headquartered in Castle Rock, US.